2021 Q1 Form 10-Q Financial Statement
#000156459021026084 Filed on May 10, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $3.130M | $1.670M |
| YoY Change | 87.43% | -54.25% |
| % of Gross Profit | ||
| Research & Development | $8.974M | $5.010M |
| YoY Change | 79.12% | -47.98% |
| % of Gross Profit | ||
| Depreciation & Amortization | $100.0K | $23.00K |
| YoY Change | 334.78% | -54.9% |
| % of Gross Profit | ||
| Operating Expenses | $12.11M | $3.563M |
| YoY Change | 239.77% | -73.16% |
| Operating Profit | -$12.11M | -$3.563M |
| YoY Change | 239.77% | -73.16% |
| Interest Expense | $301.0K | |
| YoY Change | -39.8% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | $18.00K | -$35.00K |
| YoY Change | -151.43% | -121.21% |
| Pretax Income | -$12.09M | -$6.670M |
| YoY Change | 81.26% | -49.12% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$12.09M | -$6.674M |
| YoY Change | 81.12% | 41.28% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.76 | |
| Diluted Earnings Per Share | -$0.76 | -$779.2K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 16.00M | 37.47M |
| Diluted Shares Outstanding | 16.00M |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $81.40M | $63.90M |
| YoY Change | 27.39% | -38.97% |
| Cash & Equivalents | $63.53M | $887.0K |
| Short-Term Investments | $19.20M | $24.90M |
| Other Short-Term Assets | $4.700M | $600.0K |
| YoY Change | 683.33% | -53.85% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $86.10M | $64.68M |
| YoY Change | 33.12% | -39.83% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $1.211M | $743.0K |
| YoY Change | 62.99% | -38.08% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $750.0K | $12.00K |
| YoY Change | 6150.0% | -78.95% |
| Total Long-Term Assets | $6.919M | $9.022M |
| YoY Change | -23.31% | 236.01% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $86.10M | $64.68M |
| Total Long-Term Assets | $6.919M | $9.022M |
| Total Assets | $93.02M | $73.70M |
| YoY Change | 26.21% | -33.11% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.230M | $322.0K |
| YoY Change | 903.11% | -89.8% |
| Accrued Expenses | $4.611M | $881.0K |
| YoY Change | 423.38% | -73.3% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $7.300M | |
| YoY Change | 0.0% | |
| Total Short-Term Liabilities | $8.375M | $9.900M |
| YoY Change | -15.4% | -27.88% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $6.700M |
| YoY Change | -100.0% | -50.37% |
| Other Long-Term Liabilities | $5.900M | $6.300M |
| YoY Change | -6.35% | 950.0% |
| Total Long-Term Liabilities | $5.900M | $13.00M |
| YoY Change | -54.62% | -7.8% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $8.375M | $9.900M |
| Total Long-Term Liabilities | $5.900M | $13.00M |
| Total Liabilities | $14.24M | $22.96M |
| YoY Change | -38.0% | -17.41% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$77.70M | -$399.9M |
| YoY Change | -80.57% | |
| Common Stock | $156.5M | $450.7M |
| YoY Change | -65.28% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $78.78M | $2.256M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $93.02M | $73.70M |
| YoY Change | 26.21% | -33.12% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$12.09M | -$6.674M |
| YoY Change | 81.12% | 41.28% |
| Depreciation, Depletion And Amortization | $100.0K | $23.00K |
| YoY Change | 334.78% | -54.9% |
| Cash From Operating Activities | -$11.21M | -$8.921M |
| YoY Change | 25.61% | -28.47% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $58.00K |
| YoY Change | -100.0% | 2800.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $5.250M | $18.19M |
| YoY Change | -71.14% | 2145.68% |
| Cash From Investing Activities | $5.251M | -$778.0K |
| YoY Change | -774.94% | -196.41% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 0.000 | -1.808M |
| YoY Change | -100.0% | -2003.16% |
| NET CHANGE | ||
| Cash From Operating Activities | -11.21M | -8.921M |
| Cash From Investing Activities | 5.251M | -778.0K |
| Cash From Financing Activities | 0.000 | -1.808M |
| Net Change In Cash | -5.955M | -122.0K |
| YoY Change | 4781.15% | -98.95% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$11.21M | -$8.921M |
| Capital Expenditures | $0.00 | $58.00K |
| Free Cash Flow | -$11.21M | -$8.979M |
| YoY Change | 24.8% | -28.01% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8375000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
5860000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
14235000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
534000 | |
| CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
750000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4611000 | |
| CY2021Q1 | us-gaap |
Assets
Assets
|
93019000 | |
| CY2021Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3230000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
115000000 | |
| CY2020Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1339000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
24490000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
419000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
104686000 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2634000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5843000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
15000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
156470000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-77702000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
78784000 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
93019000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
15367730 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
15367730 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8974000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
6002000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
14994000 | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
15000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
155290000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-65614000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12106000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
18000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12088000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6674000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.76 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.10 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
15996133 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1180000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5314000 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
97952000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1040000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3936000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1339000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1180000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
515000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8992000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
6091250 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
0 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
0 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-694000 | |
| CY2020Q1 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
9595000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
29000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12088000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-6674000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
73000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
23000 | |
| CY2021Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
5000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
29000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-625000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
11000 | |
| CY2021Q1 | lrmr |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
-131000 | |
| CY2020Q1 | lrmr |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
-9000 | |
| CY2021Q1 | lrmr |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-123000 | |
| CY2020Q1 | lrmr |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-2000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
331000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-11206000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8921000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
58000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
1749000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
7000000 | |
| CY2020Q1 | lrmr |
Payments Of Merger Transaction Costs
PaymentsOfMergerTransactionCosts
|
720000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
5251000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-778000 | |
| CY2020Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
18000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-5955000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-122000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
69487000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1009000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
63532000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
887000 | |
| CY2021Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
31000 | |
| CY2020Q1 | lrmr |
Offering Costs Incurred But Not Yet Paid
OfferingCostsIncurredButNotYetPaid
|
38000 | |
| CY2020Q1 | lrmr |
Merger Transaction Costs Incurred But Not Yet Paid
MergerTransactionCostsIncurredButNotYetPaid
|
644000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
448000 | |
| CY2020Q1 | lrmr |
Leasehold Improvements On Right Of Use Assets Included In Operating Lease Liability Current
LeaseholdImprovementsOnRightOfUseAssetsIncludedInOperatingLeaseLiabilityCurrent
|
7000 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. </p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. <font style="color:#000000;">The drug substance which is in frozen liquid form for CTI-1601 is currently manufactured for us by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer.  The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, we intend to use in certain of our future planned clinical trials. </font>The Company’s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</p> | |
| CY2021Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
26167000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
459000 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1350000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
689000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
924000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
105000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
160000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2021Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
6922000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
19245000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
24489000 | |
| CY2021Q1 | lrmr |
Phase1 Clinical Trial Resume Period
Phase1ClinicalTrialResumePeriod
|
2020-07 | |
| CY2021Q1 | lrmr |
Cash Cash Equivalents Marketable Securities
CashCashEquivalentsMarketableSecurities
|
81400000 | |
| CY2020 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
18000000 | |
| CY2021Q1 | lrmr |
Likelihood Percentage Minimum
LikelihoodPercentageMinimum
|
0.50 | |
| CY2020Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
628403 | |
| CY2021Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.01 | |
| CY2020Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
40595000 | |
| CY2020Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
|
1014000 | |
| CY2020Q2 | lrmr |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current And Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAndNoncurrentAssets
|
357000 | |
| CY2020Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
|
398000 | |
| CY2020Q2 | lrmr |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
|
1339000 | |
| CY2020Q2 | lrmr |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset
|
3806000 | |
| CY2020Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
|
2685000 | |
| CY2020Q2 | lrmr |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligationNoncurrent
|
5990000 | |
| CY2020Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
38834000 | |
| CY2020Q4 | lrmr |
Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
|
4460000 | |
| CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
571000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1083000 | |
| CY2021Q1 | lrmr |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
4314000 | |
| CY2020Q4 | lrmr |
Payroll Taxes Receivable
PayrollTaxesReceivable
|
32000 | |
| CY2021Q1 | lrmr |
Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
|
116000 | |
| CY2021Q1 | lrmr |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
3358000 | |
| CY2020Q4 | lrmr |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
3409000 | |
| CY2021Q1 | us-gaap |
Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
|
0 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
402550 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
14300 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2397152 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
602463 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
2397152 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
22.31 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
18.70 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
20.40 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
21.72 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
45.48 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
21.72 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
4400000 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
800000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
4400000 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1180000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
29000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
17800000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y4M13D | |
| CY2021Q1 | lrmr |
Milestone Expenses
MilestoneExpenses
|
0 | |
| CY2020Q1 | lrmr |
Milestone Expenses
MilestoneExpenses
|
0 | |
| CY2021Q1 | lrmr |
Milestone Liability
MilestoneLiability
|
0 | |
| CY2020Q1 | lrmr |
Milestone Liability
MilestoneLiability
|
0 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y3M18D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y7M6D | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.110 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.110 | |
| CY2021Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
100000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
884000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1197000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1146000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1065000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
9689000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
3295000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
6394000 |
